CoChat

New features in MEK retinopathy

Open access
Tyagi, Pallavi, Santiago, Cynthia · 2018 · BMC Ophthalmology

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic alterations in signal transduction pathways, hence less generalised toxicity. Dabrafenib, a BRAF inhibitor and Trametinib, a MEK inhibitor are two molecularly targeted agents recently approved for treatment of advanced, unresectable melanomas. MEK retinopathy is a recently introduced term describing retinal toxicity secondary to MEK inhibitors. CASE PRESENTATION: A 71-year-old man presented with 'circular, green patches' in his central vision for 2 weeks. He had multiple relapsed stage IV BRAF gene mutant malignant melanoma. He was on treatment with Dabrafenib (Tafinlar) for 7 months and Trametinib (Mekinist) for 4 months respectively. The fundus looked normal. The OCT scan showed bilateral symmetrical cystoid macular edema, intraretinal and subretinal fluid, thickening of elliposoid zone and subretinal granular deposits. The symptoms resolved with temporary cessation of chemotherapy but OCT signs persisted. CONCLUSION: This case report identifies two new remarkable features of MEK retinopathy as thickening of ellipsoid zone and 'starry sky' pattern of distribution of subretinal granular deposits. These changes signify photoreceptors/ RPE toxicity and dysfunction. The subretinal granular deposits showed increased autofluorescence suggested abnormal lipofuscin clearance due to RPE dysfunction. The molecularly targeted therapy has revolutionized the cancer treatment and increased the survival rate. These agents are relatively new and recently approved for clinical use and most of them are associated with ocular toxicities. Awareness of ocular symptoms, side-effect profile of drugs, monitoring regime and liaison between oncologist and eye care professional with ocular imaging is key to early diagnosis and management of ocular adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12886-018-0861-8

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 OCT image at presentation: Bilateral cystoid macular edema at presentation
Fig. 1 OCT image at presentation: Bilateral cystoid macular edema at presentationCC BY · PubMed Central
Fig. 2 Fundus appearance: Healthy optic disc, dull foveal reflex and normal vasculature
Fig. 2 Fundus appearance: Healthy optic disc, dull foveal reflex and normal vasculatureCC BY · PubMed Central
Fig. 3 OCT images 5 days after stopping treatment: Intra-retinal and sub-retinal fluid, thickening of ellipsoid zone, sub-retinal deposits and multiple hyper-fluorescent spots on IRR image
Fig. 3 OCT images 5 days after stopping treatment: Intra-retinal and sub-retinal fluid, thickening of ellipsoid zone, sub-retinal deposits and multiple hyper-fluorescent spots on IRR imageCC BY · PubMed Central
Fig. 4 Autofluorescence image: Increased autofluorescence of scattered sub-retinal granular deposits in macular area
Fig. 4 Autofluorescence image: Increased autofluorescence of scattered sub-retinal granular deposits in macular areaCC BY · PubMed Central
Fig. 5 Change in OCT appearance in both eyes over 6 months: Resolution of cystoid macular edema in perifoveal region, reduction in the intra-retinal and sub-retinal fluid. The ellipsoid zone thickening and subretinal granular deposits remained unchanged in right (a) and left (b) eye
Fig. 5 Change in OCT appearance in both eyes over 6 months: Resolution of cystoid macular edema in perifoveal region, reduction in the intra-retinal and sub-retinal fluid. The ellipsoid zone thickening and subretinal granular deposits remained unchanged in right (a) and left (b) eyeCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 39

Metadata

Authors
Tyagi, P., & Santiago, C.
Affiliations
Aberdeen Royal Infirmary (GB)
Corresponding author
Tyagi, Pallavi
Venue
BMC Ophthalmology
Published
2018-09
Volume
18
Issue
S1
Pages
221-221
ISSN
1471-2415 (ISSN-L)
OpenAlex
W2890507526
Cited by
39
References
17
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 3 · 2018: 1
FWCI
5.03
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • BMC Ophthalmology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
trametinib, dabrafenib, BRAF inhibitors, melanoma, retinal toxicity, cystoid macular edema, retinal pigment epithelium dysfunction, autofluorescence, ocular adverse effects, targeted therapy
MeSH terms
Aged, Humans, Imidazoles, Macular Edema, Male, Oximes, Pyridones, Pyrimidinones, Retinal Diseases, Skin Neoplasms, Photoreceptor Cells, Vertebrate, Mitogen-Activated Protein Kinase Kinases, Tomography, Optical Coherence, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Retinal Pigment Epithelium, Subretinal Fluid, Molecular Targeted Therapy, Paraneoplastic Syndromes, Ocular

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New features in MEK retinopathy. https://app.cochat.ai/papers/10.1186/s12886-018-0861-8
The paper
Tyagi, P., & Santiago, C. (2018). New features in MEK retinopathy. BMC Ophthalmology. https://doi.org/10.1186/s12886-018-0861-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.